NCT06876142 2026-04-22
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Suspended
Clinical Trials
7 trialsNCT07539441 2026-04-20
A Study of Mirdametinib in People With Central Nervous System Tumors
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT06159166 2026-04-13
Mirda
Johns Hopkins University
Phase 1/2 Recruiting
NCT07061951 2026-04-13
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07521657 2026-04-13
NF118
University of Alabama at Birmingham
Phase 2 Not yet recruiting
NCT03962543 2026-04-08
ReNeu
SpringWorks Therapeutics, Inc.
Phase 2 Active not recruiting
NCT05028166 2026-03-27
Individual Patient Compassionate Use of Mirdametinib
SpringWorks Therapeutics, Inc.
Available